The advent of delta-8 THC and the issues it poses to treatment court abstinence monitoring is a harbinger of things to come. On the horizon are numerous cannabinoid-related products already commercially available, including delta-10 THC, THC-O, THC-P, and THC-V. With little or no regulatory oversight, scant research into the effects of these compounds, few legal restrictions, and limited testing capabilities, the courts, in their supervisory role, must be willing to prohibit a wide range of cannabinoid-related products to ensure proper interpretation of abstinence monitoring strategies.

Author:

Paul L. Cary, M.S.
Forensic Toxicologist

Date: 2021